Warning: The NCBI web site requires JavaScript to function. more...
The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.
Ruderman EM, Pope RM.
Arthritis Res Ther. 2005;7 Suppl 2:S21-5. Epub 2005 Mar 16. Review.
Related citations
Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis.
Korhonen R, Moilanen E.
Basic Clin Pharmacol Toxicol. 2009 Apr;104(4):276-84. Epub 2009 Feb 18. Review.
Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis?
Malmström V, Trollmo C, Klareskog L.
Arthritis Res Ther. 2005;7 Suppl 2:S15-20. Epub 2005 Mar 16. Review.
Technology evaluation: abatacept, Bristol-Myers Squibb.
Dumont FJ.
Curr Opin Mol Ther. 2004 Jun;6(3):318-30. Review.
Role of abatacept in the management of rheumatoid arthritis.
Nogid A, Pham DQ.
Clin Ther. 2006 Nov;28(11):1764-78. Review.
Abatacept: a novel therapy approved for the treatment of patients with rheumatoid arthritis.
Lundquist L.
Adv Ther. 2007 Mar-Apr;24(2):333-45. Review.
Drug Insight: abatacept for the treatment of rheumatoid arthritis.
Nat Clin Pract Rheumatol. 2006 Dec;2(12):654-60. Review.
Abatacept in the treatment of rheumatoid arthritis.
Buch MH, Vital EM, Emery P.
Arthritis Res Ther. 2008;10 Suppl 1:S5. Epub 2008 Oct 15. Review.
[Effect of CTLA4-Ig on radiographic outcome of patients with rheumatoid arthritis].
Harigai M.
Clin Calcium. 2007 Apr;17(4):577-84. Review. Japanese.
Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists.
Scheinfeld N.
J Dermatolog Treat. 2006;17(4):229-34. Review.
CTLA-4Ig: uses and future directions.
Ben-Shoshan M.
Recent Pat Inflamm Allergy Drug Discov. 2009 Jun;3(2):132-42.
T cells of staphylococcal enterotoxin B-tolerized autoimmune MRL-lpr/lpr mice require co-stimulation through the B7-CD28/CTLA-4 pathway for activation and can be reanergized in vivo by stimulation of the T cell receptor in the absence of this co-stimulatory signal.
Zhou T, Weaver C, Linsley PS, Mountz JD.
Eur J Immunol. 1994 May;24(5):1019-25.
Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept.
Fiocco U, Sfriso P, Oliviero F, Pagnin E, Scagliori E, Campana C, Dainese S, Cozzi L, Punzi L.
Autoimmun Rev. 2008 Oct;8(1):76-82. Epub 2008 Aug 15. Review.
Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig.
Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ.
J Clin Invest. 1995 Aug;96(2):987-93.
[Pharmacological properties and clinical efficacy of abatacept (Orencia(®)) for the treatment of rheumatoid arthritis].
Yasuoka Y, Goto A, Seriu T.
Nihon Yakurigaku Zasshi. 2011 Feb;137(2):87-94. Review. Japanese. No abstract available.
Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis.
Choy EH.
Clin Exp Rheumatol. 2009 May-Jun;27(3):510-8. Review.
[CTLA4-Ig (abatacept)].
Nihon Rinsho. 2007 Jul;65(7):1231-7. Review. Japanese.
Interference with CD28, CD80, CD86 or CD152 in collagen-induced arthritis. Limited role of IFN-gamma in anti-B7-mediated suppression of disease.
Tellander AC, Pettersson U, Runström A, Andersson M, Michaëlsson E.
J Autoimmun. 2001 Aug;17(1):39-50.
Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation.
Salomon B, Bluestone JA.
Annu Rev Immunol. 2001;19:225-52. Review.
Costimulation blockade in autoimmunity and transplantation.
Vincenti F.
J Allergy Clin Immunol. 2008 Feb;121(2):299-306; quiz 307-8. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on